Toshiyuki Ikemoto Author

Case Report Subscription

Dasatinib Monotherapy to Maintain Complete Remission before Allogeneic Bone Marrow Transplantation under Monitoring of the Blastic Chronic Myelogenous Leukemia Biphenotypic Cells and Bcr-Abl Transcripts

Author(s):

Shinichiro Kawamoto, Noboru Yonetani, Ryota Masutani,Toshiyuki Ikemoto and Takayuki Takubo

Dasatinib Monotherapy to Maintain Complete Remission before Allogeneic Bone Marrow Transplantation under Monitoring of the Blastic Chronic Myelogenous Leukemia Biphenotypic Cells and Bcr-Abl Transcripts

A 49-year-old male with blastic phase chronic myelogenous leukemia (CML-BP) with CD13/CD19 double-positive markers was treated with a combination of tyrosine kinase inhibitors and chemotherapy, followed by allogeneic bone marrow transplantation (allo-BMT). The biphenotypic cells and bcr-abl transcripts were monitored during the treatment course, and the efficacy of dasatinib for the treatment of the allo-BMT eligible CML-BP patient was evaluated. Following a single course of hyper-CVAD/MA with imatinib mesylate, the biphenotypic cells and bcr-abl mRNA decreased... view more»

DOI: 10.4172/lpma.1000106

Abstract HTML PDF